Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

Business Wire

02-18

AUSTIN, Texas, February 18, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Earnings Conference Call Information

Event:		Natera’s Fourth Quarter & Full Year 2024 Financial Results
Date:		February 27, 2025
Time:		1:30 p.m. PT (4:30 p.m. ET)
Live Dial-In:		1-888-770-7321 (Domestic)
		1-929-201-7101 (International)
Conference ID:		7684785
Webcast:		https://events.q4inc.com/attendee/538630796

A webcast replay will be available at investor.natera.com.

About Natera

Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218525659/en/

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512175165"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512175165\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512175165?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-18 22:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2512175165","market":"us","top_or_hot":-1,"title":"Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"200\" src=\"https://s.yimg.com/uu/api/res/1.2/FJ2DRN0_NLIBz6VXCS8OjA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/972705011c1df2255a8b350291939eda\" title=\"\" width=\"200\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>AUSTIN, Texas, February 18, 2025</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/NTRA\">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).</p>\n<p><b>Earnings Conference Call Information</b></p>\n<table cellspacing=\"0\">\n<tbody>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Event:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>Natera’s Fourth Quarter &amp; Full Year 2024 Financial Results</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Date:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>February 27, 2025</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Time:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>1:30 p.m. PT (4:30 p.m. ET)</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Live Dial-In:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>1-888-770-7321 (Domestic)</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>1-929-201-7101 (International)</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Conference ID:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>7684785</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Webcast:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>https://events.q4inc.com/attendee/538630796</p></td>\n</tr>\n</tbody>\n</table>\n<p>A webcast replay will be available at investor.natera.com.</p>\n<p><b>About Natera</b></p>\n<p>Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250218525659/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com <br/>Media: Lesley Bogdanow, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> of Corporate Communications, Natera, Inc., pr@natera.com<br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera to Report its Fourth Quarter and Full Year Results on February 27, 2025\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2025-02-18 22:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body>\n<figure>\n<img border=\"0\" height=\"200\" src=\"https://s.yimg.com/uu/api/res/1.2/FJ2DRN0_NLIBz6VXCS8OjA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/972705011c1df2255a8b350291939eda\" title=\"\" width=\"200\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>AUSTIN, Texas, February 18, 2025</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/NTRA\">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).</p>\n<p><b>Earnings Conference Call Information</b></p>\n<table cellspacing=\"0\">\n<tbody>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Event:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>Natera’s Fourth Quarter &amp; Full Year 2024 Financial Results</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Date:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>February 27, 2025</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Time:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>1:30 p.m. PT (4:30 p.m. ET)</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Live Dial-In:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>1-888-770-7321 (Domestic)</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>1-929-201-7101 (International)</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Conference ID:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>7684785</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Webcast:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>https://events.q4inc.com/attendee/538630796</p></td>\n</tr>\n</tbody>\n</table>\n<p>A webcast replay will be available at investor.natera.com.</p>\n<p><b>About Natera</b></p>\n<p>Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250218525659/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com <br/>Media: Lesley Bogdanow, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> of Corporate Communications, Natera, Inc., pr@natera.com<br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/natera-report-fourth-quarter-full-140000252.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/natera-report-fourth-quarter-full-140000252.html","article_id":"2512175165","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512175165","pubTimestamp":1739887200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AUSTIN, Texas, February 18, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT .Natera’s Fourth Quarter & Full Year 2024 Financial Results. Natera is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments  in Austin, Texas, and San Carlos, California. For more i","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Natera将于2025年2月27日公布第四季度和全年业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLIA":1,"NTRA":1},"content_text":"AUSTIN, Texas, February 18, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).\nEarnings Conference Call Information\n\n\n\nEvent:\n\nNatera’s Fourth Quarter & Full Year 2024 Financial Results\n\n\nDate:\n\nFebruary 27, 2025\n\n\nTime:\n\n1:30 p.m. PT (4:30 p.m. ET)\n\n\nLive Dial-In:\n\n1-888-770-7321 (Domestic)\n\n\n\n\n1-929-201-7101 (International)\n\n\nConference ID:\n\n7684785\n\n\nWebcast:\n\nhttps://events.q4inc.com/attendee/538630796\n\n\n\nA webcast replay will be available at investor.natera.com.\nAbout Natera\nNatera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250218525659/en/\nContacts\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}